fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

MCCH Sleep Disorders Center in Murray Receives Program Accreditation

MURRAY, Ky. (7/3/15) — Murray-Calloway County Hospital Sleep Disorders Center in Murray recently received program… Read More

Public Meeting to Discuss Alternatives for Road Improvements Set for Tuesday

OWENSBORO, Ky. (7/4/15) — The Kentucky Transportation Cabinet has scheduled a public information meeting to discuss… Read More
1 DOW 17,730.11
-27.80 (-0.16%)    
2 S&P 2,076.78
-0.64 (-0.03%)    
3 NASDAQ 5,009.21
0.00 (0.00%)    

Most Read This Week

July 02, 2015 14722

Emergency Response Team on Scene of Standoff on…

by Doreen Dennis, SurfKY News
July 02, 2015 7082

Police: Stand Off Suspect in Critical Condition

by Doreen Dennis, SurfKY News
June 29, 2015 5372

UPDATE: Victim of Home Invasion/Homicide Died of…

by SurfKY News
June 29, 2015 4122

Accused Synthetic Marijuana Traffickers Appear in…

by Doreen Dennis, SurfKY News
June 28, 2015 3664

'Curb Service’ at Local Eatery Ends with DUI…

by Doreen Dennis, SurfKY News

Most Read This Month

June 24, 2015 45407

Western Kentucky, Southern Indiana's Largest…

by Doreen Dennis, SurfKY News
July 02, 2015 14722

Emergency Response Team on Scene of Standoff on…

by Doreen Dennis, SurfKY News

Stories Trending Now

July 03, 2015 3264

KMA Reminds Motorists of New Kentucky Red Light…

by David Holt
July 03, 2015 1257

Planning Commission Approves Re-zoning…

by Tammy Holloway, SurfKY News
July 03, 2015 1123

County Clerk Warns of Telephone Scam in Hopkins…

by Keenan Cloern
July 04, 2015 1074

Happenings and Meetings – Hopkins County

by Tammy Holloway, SurfKY News
July 03, 2015 1020

States Where Motorcycles Can Run Red Lights…

by Michelle Megna
July 03, 2015 985

UPDATE - Suspicious Package under Investigation

by SurfKY News
July 04, 2015 941

Heavy Rains Flood Streets Around Town

by Doreen Dennis, SurfKY News
July 03, 2015 703

Pet of the Day

by Natalie Ostrander
July 03, 2015 557

Beechmont All Stars Defeat Auburn All Stars 10-2

by Mike Groves, SurfKY News
July 03, 2015 552

Central City All Stars Top Bremen All Stars 8-5

by Mike Groves, SurfKY News